NinePointTwo Capital’s Amedisys AMED Stock Holding History

NinePointTwo Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,499	Closed	-$257K	–	247
2023 Q1	$257K	Buy	+3,499	New	+$303K	0.1%	119

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

NinePointTwo Capital's AMED Position: Q2 2023 in Review

NinePointTwo Capital sold out of Amedisys (AMED) in Q2 2023, closing a stake of 3,499 shares — an estimated $257K sold.

NinePointTwo Capital first reported a position in AMED in Q1 2023 and held it in 1 quarter. The position peaked at $257K in Q1 2023. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

NinePointTwo Capital reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
NinePointTwo Capital sold 3,499 Amedisys shares in Q2 2023, an estimated $257K.
NinePointTwo Capital first reported a position in Amedisys in Q1 2023 and held it in 1 quarter.
NinePointTwo Capital's Amedisys position peaked at $257K in Q1 2023.
301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on NinePointTwo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.